NewsdeskProteasome inhibitor for treatment of multiple myeloma
References (0)
Cited by (6)
Ubiquitin receptors and protein quality control
2013, Journal of Molecular and Cellular CardiologyCitation Excerpt :Recently, a small chemical compound (IU1) capable of inhibiting USP14 deubiquitination was shown to enhance proteasome-mediated degradation of some substrates, including several proteins associated with neural degenerative diseases [106]. This represents the invent of the first pharmacological proteasome activator, although proteasome inhibitors are used clinically to treat certain forms of cancer [107]. It remains to be determined whether IU1 or alike can enhance proteasome function in animals, and whether it is effective in treating disease with proteasome functional insufficiency (PFI).
Protein Quality Control in Cardiomyocytes
2012, Muscle: Fundamental Biology and Mechanisms of DiseaseInhibition of Nek2 by Small Molecules Affects Proteasome Activity
2014, BioMed Research InternationalProteasome functional insufficiency in cardiac pathogenesis
2011, American Journal of Physiology - Heart and Circulatory PhysiologyProteasome β subunit pharmacogenomics: Gene resequencing and functional genomics
2008, Clinical Cancer ResearchHeart failure and protein quality control
2006, Circulation Research
Copyright © 2005 Published by Elsevier Ltd. All rights reserved.